VILDAGLIPTIN

▸ Vildafast-M  is Inhibits dipeptidyl peptidase-4 and prevents degradation of glucagon like peptide-1 in patients with type 2 diabetes mellitus

No accumulation of drug is seen following the administration of multiple doses because of short elimination life

▸Vildafast-M Does not possess adverse gastrointestinal events compliance and adherence to patients improves

METFORMIN

▸ First line therapy for patients with Type 2 Diabetes Mellitus

▸ Combination therapy reduces the pill burden and improves patient compliance